August 31, 2016 10:31 PM ET

Pharmaceuticals

Company Overview of Icon Bioscience Inc.

Company Overview

Icon Bioscience Inc., a biopharma company, develops and commercializes intraocular ophthalmic products based on its Verisome drug delivery technology. Its products target various ophthalmic indications, including glaucoma, macular edema, inflammation/infection associated with cataract surgery, and age-related macular degeneration. The company was incorporated in 2004 and is based in Sunnyvale, California.

1253 Reamwood Avenue

Sunnyvale, CA 94089

United States

Founded in 2004

Phone:

408-734-8188

Fax:

408-734-8188

Key Executives for Icon Bioscience Inc.

Chief Executive Officer and President
Age: 52
Vice President of Clinical & Medical Affairs
Manufacturing & Operations Advisor
Advisor
Age: 69
Vice President of Quality & Compliance
Compensation as of Fiscal Year 2016.

Icon Bioscience Inc. Key Developments

Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090

Icon Bioscience Inc. announced that Phase 3 data showed significantly positive outcomes for IBI-10090 compared to placebo in treating inflammation associated with cataract surgery. The Phase 3 study of IBI-10090, completed in the fourth quarter of 2014, was a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial involving 394 patients. The ensuing analysis of data shows IBI-10090 - with regard to both primary and secondary study endpoints - to be safe as well as highly effective. IBI-10090 utilizes the Verisome technology to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery. With over 3 million cataract surgeries in the US annually and with the standard of care for associated inflammation being a comparably burdensome, protracted process of multiple daily eye drops, IBI-10090 addresses a clear medical need in a large ophthalmic pharmaceutical space.

Icon Bioscience, Inc. Completes Treatment in its Pivotal Phase 3 Study of IBI-10090

Icon Bioscience, Inc. announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. Top-line data is expected to be reported in the fourth quarter of 2014. Employing Icon's Verisome technology, IBI-10090 is designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 19, 2015
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Icon Bioscience Inc., please visit iconbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.